<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277289</url>
  </required_header>
  <id_info>
    <org_study_id>Crodex01</org_study_id>
    <secondary_id>2008-007329-38</secondary_id>
    <nct_id>NCT01277289</nct_id>
  </id_info>
  <brief_title>Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease</brief_title>
  <acronym>Crodex</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Parallel-group Study of Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erydel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erydel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the assessment of the efficacy of Ery-Dex (dexamethasone
      intra-erythrocyte) versus placebo in maintaining patients with steroid-dependent Crohn's
      disease in clinical remission throughout 12 months without oral steroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The medical treatment of Crohn's disease is still unsatisfactory despite the use of large
      number of drugs as steroids which cause several side effects after a long-term
      treatment.Ery-Dex thanks its peculiar way of administration (intra-erythrocyte encapsulation
      and release at very low doses during 1 month)should dramatically reduce side effects due
      steroids, which are dose dependent, and provide an alternative for long-term glucocorticoid
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to the big difficulty to enrol suitable patients
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients maintaining steroids-free clinical remission (CDAI&lt;150) without surgery for 12 months</measure>
    <time_frame>after 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of safety by comparison of treatment emergent AE</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients interrupting the study because of adverse events</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of the period of clinical remission</measure>
    <time_frame>after 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dosing of serum cortisol</measure>
    <time_frame>after 12 months</time_frame>
    <description>basal and following ACTH trigger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of inflammation indexes (ESR, CRP)</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Ery-dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>500 mg/20 ml encapsulated in erythrocytes, every month for 12 months</description>
    <arm_group_label>Ery-dex</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Ery-dex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female patients;

          -  age &gt; 18 years

          -  patients with steroid-dependent CD in clinical remission showing a relapse in the last
             12 months and in treatment with 10mg of methylprednisone at least

          -  patients willing and able to give written informed consent

        Exclusion Criteria:

          -  CD with intestinal sub-occlusion, or suspected abdominal abcess, or active perianal
             disease or CDAI &gt;150

          -  pts. already on therapy with immunosuppressant agents for less than 4 months

          -  pts. receiving Infliximab (or other anti-TNF) in the previous 3 months

          -  severe concomitant diseases

          -  elective surgery already scheduled at the start of the study

          -  chronic use of alcohol; drug addiction

          -  pregnant women

          -  subjects with contra-indication to the use of steroids

          -  investigational treatments in the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Andriulli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unafilliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni Pierantoni</name>
      <address>
        <city>Forl√¨</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complesso Integrato Columbus</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean De Urgenta</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic CIBER EHD</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dexamethasone</keyword>
  <keyword>ery-dex</keyword>
  <keyword>Chron's disease</keyword>
  <keyword>CD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

